LncRNA-MIR503HG as a marker for predicting lymph node metastasis in renal papillary cell carcinoma
By using LncRNA-MIR503HG as a biomarker and detection kit, the problem of predicting lymph node metastasis in renal papillary cell carcinoma was solved, and accurate prediction of lymph node metastasis risk and improved survival time were achieved.
Patent Information
- Application Number
- CN202210960057.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-08-11
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2042-08-11
AI Technical Summary
The lack of effective biomarkers in the prior art to predict lymph node metastasis in renal papillary cell carcinoma leads to low diagnostic sensitivity and large differences in treatment individuals.
LncRNA-MIR503HG is used as a biomarker for predicting lymph node metastasis in renal papillary cell carcinoma, and a kit is developed to detect its expression levels to predict lymph node metastasis events and distant by detecting the expression levels of LncRNA-MIR503HG in renal cancer tissues of patients. Prognosis.
By detecting the expression level of LncRNA-MIR503HG, it can effectively predict the risk of lymph node metastasis and survival in patients. Early detection of low expression patients can be treated in advance to improve survival time.
Smart Images

Figure CN115992233B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of bioengineering and relates to a biomarker, specifically to the use of LncRNA-MIR503HG as a marker for predicting lymph node metastasis of papillary renal cell carcinoma and a diagnostic kit for detecting LncRNA-MIR503HG.
[0002] Background Information
[0003] Renal cell carcinoma (RCC) originates from renal tubular epithelial cells and is one of the most common malignant tumors of the urinary system, accounting for 2-3% of new malignant tumors each year. In recent years, the incidence and mortality of RCC have shown an increasing trend year by year.
[0004] Papillary renal cell carcinoma (pRCC) is a common special pathological type of the most common renal malignant tumor in the urinary system. Unlike common clear cell carcinoma, this pathological type has an extremely high rate of lymph node metastasis, and lymph node metastasis is one of the most important factors affecting the prognosis of patients with renal cancer. For many solid tumors, distant organ metastasis of the tumor indicates that the disease has entered the late stage and is the primary factor leading to tumor-related death. Lymph node metastasis is a harbinger of distant metastasis of the tumor and can be used as an important prognostic indicator. At present, the diagnosis and treatment of lymph node metastasis have problems such as low sensitivity of imaging diagnosis, large trauma and complications of extended dissection, and large individual differences in drug treatment sensitivity. Therefore, studying the molecular mechanisms related to lymph node invasion and metastasis is of great clinical significance for improving the prognosis of patients with papillary renal cell carcinoma.
[0005] Studies have shown that long non-coding RNA (LncRNA) plays an important role in regulating the invasion and metastasis of renal cancer. Long non-coding RNA (LncRNAs) are a class of RNA molecules with a transcript length of more than 200 nt. They do not encode proteins, but regulate gene expression levels at multiple levels (epigenetic regulation, transcriptional regulation, and post-transcriptional regulation) in the form of RNA.
[0006] LncRNA has received extensive attention in the field of tumors. Existing studies have demonstrated the various regulatory modes of LncRNA: 1) transcription from the upstream promoter region of protein-coding genes, interfering with the expression of downstream genes; 2) inhibiting RNA polymerase II or mediating chromatin remodeling and histone modification, affecting the expression of downstream genes; 3) forming complementary duplexes with the transcripts of protein-coding genes, interfering with the splicing of mRNA, and forming different splicing forms; 4) forming complementary duplexes with the transcripts of protein-coding genes, and producing endogenous siRNA under the action of Dicer enzyme; 5) binding to specific proteins, LncRNA transcripts can regulate the activity of the corresponding proteins; 6) forming nucleic acid-protein complexes with proteins as structural components; 7) binding to specific proteins, changing the cellular localization of the protein; 8) acting as a precursor molecule of small molecule RNA (such as miRNA, piRNA); 9) interacting with miRNA as a competing endogenous RNA (ceRNA), participating in the expression regulation of target genes, etc.
[0007] The abnormal expression of long non-coding RNA (LncRNAs) has become a hot topic in human cancer research, and a variety of LncRNAs are involved in tumor angiogenesis, invasion and metastasis. However, in the field of renal papillary cell carcinoma, there are no research reports on LncRNA related to lymph node metastasis at home and abroad. The basic experiments related to LncRNA-MIR503HG conducted by the applicant have obtained preliminary results and demonstrated good predictive efficacy. This renal papillary cell carcinoma-specific LncRNA may become a predictive target for lymph node metastasis events and even tumor progression, ultimately bringing treatment opportunities to clinical patients. Summary of the invention
[0008] The purpose of the present invention is to provide a newly discovered LncRNA-MIR503HG as a biomarker for predicting the progression of lymph node metastasis of renal papillary cell carcinoma, and the use is to solve the technical problem that there is no suitable biomarker in the prior art to predict lymph node metastasis of renal papillary cell carcinoma.
[0009] The present invention provides use of LncRNA-MIR503HG in preparing a biomarker for predicting the progression of lymph node metastasis of renal papillary cell carcinoma.
[0010] The present invention also provides use of a reagent for detecting LncRNA-MIR503HG in preparing a kit for predicting the progression of lymph node metastasis of renal papillary cell carcinoma, wherein the upstream primer sequence for detecting LncRNA-MIR503HG is shown in SEQ ID NO.1, and the downstream primer sequence for detecting LncRNA-MIR503HG is shown in SEQ ID NO.2; the internal reference used for detection is β-actin, the upstream primer sequence for detecting β-actin is shown in SEQ ID NO.3, and the downstream primer sequence for detecting β-actin is shown in SEQ ID NO.4.
[0011] Compared with the prior art, the technical effect of the present invention is positive and obvious. The present invention can understand the patient's lymph node metastasis events and long-term prognosis by detecting the expression level of LncRNA-MIR503HG in the patient's renal cancer tissue. The present invention found that in the renal papillary cell carcinoma population, patients with low expression of LncRNA-MIR503HG are more likely to have lymph node metastasis than patients with high expression of MIR503HG, with relatively low PFS and poor survival. Therefore, early detection of low-expression patients can be carried out in advance for surgery, radiotherapy, targeted treatment and other treatments, which can improve survival time. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 It shows that MIR503HG is a newly discovered LncRNA with low expression in pRCC tumor tissues. A: Three pRCC-specific LncRNAs obtained from the GEPIA database; B: The specific expression of MIR503HG in renal papillary cell carcinoma cell lines evaluated according to the CCLE database.
[0013] Figure 2 The correlation between MIR503HG and lymph node metastasis-related factor VEGFC is shown. A: ELISA experiment determined the level of VEGFC secreted by ACHN and CAKI-2 cells after siRNA treatment; B: WB experiment determined the total level of VEGFC protein in ACHN and CAKI-2 cells after siRNA treatment;
[0014] Figure 3 The effects of knockdown and overexpression of MIR503HG on the migration and invasion of pRCC cells were detected. A. The migration ability of ACHN and CAKI-2 cells in different treatment groups was determined by scratch assay. B: ACHN and CAKI-2 cells were transfected with si-MIR503HG and si-NC (ACHN) or oe-MIR503HG and mock (CAKI-2), and then the invasion ability was compared by transwell assay.
[0015] Figure 4 The correlation between MIR503HG levels and clinical events is shown. A: The expression level of MIR503HG in lymph node metastasis / non-metastasis and high / low pathological grade was detected by qRT-PCR; Kaplan-Meier analysis compared the progression-free survival of patients with high and low expression levels in pRCC; B: ISH experiment compared the transcription level of MIR503HG in pRCC samples with lymph node metastasis and adjacent normal renal tissues.
[0016] Figure 5 The lymphatic endothelial cells were co-cultured with the culture system of the pRCC cell line (transfected with si-MIR503HG / overexpressed with MIR503HG plasmid), and the tube formation ability of the lymphatic endothelial cells was further detected by the tube formation experiment. DETAILED DESCRIPTION
[0017] Example 1 MIR503HG is a newly discovered LncRNA that can inhibit the progression of renal papillary cell carcinoma
[0018] In order to find potential LncRNAs involved in the progression of pRCC, we selected the renal papillary cell carcinoma-related dataset from the GEPIA database (integrating the TCGA database + GTEx database), systematically analyzed the differentially expressed LncRNAs between pRCC tissues and paired normal renal tissues, and further verified them in the cell line database.
[0019] Figure 1 A, By setting the search conditions: Log2FC absolute value > 2, and P < 0.01; specifically down-regulated in the papillary cell carcinoma database and no difference was found in non-clear cell carcinoma or chromophobe cell carcinoma; the top 3 LncRNAs were further screened.
[0020] We focused on three potential LncRNAs in the papillary cell carcinoma database (TCGA-KIRP dataset): RP11-334E6.12, AC006126.4, and MIR503HG (the complete sequence transcript length of MIR503HG is 786 bp, as shown in SEQ ID NO.5).
[0021] Figure 1 B According to the CCLE database, in renal papillary cell carcinoma cell lines such as CAKI-2, ACHN, and UO31, the expression of MIR503HG was specifically reduced in pRCC cell lines compared with ccRCC cell lines.
[0022] Example 2 At the cellular level, MIR503HG is correlated with lymph node metastasis factor VEGFC.
[0023] 1) The expression of RP11-334E6.12, AC006126.4, and MIR503HG in ACHN and CAKI-2 was knocked down using siRNA and lentiviral knockdown (KD) technology to obtain knockdown and control groups.
[0024] 2) ELISA identification of the differences in extracellular secretion levels of VEGFC protein among different groups: identification was performed using an ELISA kit.
[0025] 3) Western blot identification of the overall expression difference of VEGFC protein among different groups: using VEGFC antibody, identification was performed using Western blot kit.
[0026] We found that: Figure 2 As shown in Figure 2, after knocking down MIR503HG in ACHN and CAKI-2 cell lines, ELISA results significantly upregulated VEGFC protein secretion ( Figure 2 A), while knockdown of RP11-334E6.12 and AC006126.4 showed no significant difference. Then Western blot was performed, as shown in Figure 2 As shown in B, the expression of VEGFC can be detected to be upregulated. At the same time, after overexpression of MIR503HG, VEGFC was significantly downregulated. The above results show that the present invention successfully verifies that the level of MIR503HG is negatively correlated with the lymph node metastasis-related factor VEGFC. *P<0.05.
[0027] Example 3 MIR503HG inhibits the migration and invasion ability of pRCC cells.
[0028] In vitro cell migration assay (cell scratch assay)
[0029] When ACHN or CAKI-2 cells reached more than 90% confluence, a sterile 200 μl pipette tip was used to scratch the monolayer of cells formed in the center of the well along the ruler. The scratched cells were washed with PBS, and new serum-free medium was replaced to continue cell culture. The scratched area was photographed at 0 hours and 24 hours, and the migration ability was calculated using the formula.
[0030] Calculation formula: (1-[current wound size / initial wound size])×100. In vitro cell invasion assay (Transwell assay)
[0031] 1) Coating basement membrane: Dilute 50 mg / L Matrigel gel at a ratio of 1:8, and apply 20 μl of the gel evenly on the upper chamber surface of the bottom membrane of the Transwell chamber. Incubate at 37°C for 30 minutes to solidify the gel.
[0032] 2) Preparation of cell suspension: Before preparing the cell suspension, the cells can be starved for 24 hours to further remove the influence of serum; digest the cells, centrifuge and discard the culture medium after terminating the digestion, wash the cells with PBS twice and mix them with serum-free culture medium, and count the cell density with a cell counting instrument.
[0033] 3) Inoculation of cells: Add 200ul of cell suspension to each well of the chamber (8μm pore size) and the number of cells is 1×10 5 600ul of culture medium containing 10% FBS was added to the outer chamber of the 24-well plate.
[0034] 4) After incubation at 37°C for 24 hours, remove the chamber and discard the supernatant.
[0035] 5) Wipe off the matrix gel and cells in the upper chamber with a cotton swab, fix the chamber in 4% paraformaldehyde for 30 min, and then wash with PBS.
[0036] 6) Crystal violet staining: Immerse the chamber in a 0.1% crystal violet solution for 15-30 minutes. Take out the chamber, wash it three times with PBS, and wipe off the cells on the inner side that have not migrated.
[0037] 7) Counting: Take 5 high-power fields under a microscope to count the number of cells stained with crystal violet and take photos.
[0038] We found that knocking down MIR503HG can promote the invasion and metastasis phenotype of pRCC. Figure 3 As shown in A, the scratch assay showed that knocking down MIR503HG significantly promoted the migration ability of ACHN and CAKI-2 cells, while overexpression of MIR503HG inhibited the migration ability of cells. Figure 3 As shown in B, Transwell invasion assay showed that knockdown of MIR503HG significantly promoted the invasion ability of ACHN and CAKI-2 cells, while overexpression of MIR503HG inhibited the invasion ability of cells. *P<0.05.
[0039] Example 4 Distribution of MIR503HG in patients at different clinical stages and its relationship with lymph node metastasis
[0040] To further explore the relationship between MIR503HG expression and clinicopathological characteristics of pRCC patients, we analyzed the expression of MIR503HG in 67 pRCC tissues.
[0041] qRT-PCR was used to further verify the expression of MIR503HG in pRCC tissues of patients with different clinical outcomes and clinicopathological characteristics
[0042] Testing process:
[0043] Total RNA was extracted from frozen tissue specimens using Trizol reagent, and reverse transcribed into cDNA using a reverse transcription kit. qRT-PCR was performed on a 7900HT Fast Real-Time PCR instrument, using β-actin as an internal reference. -ΔΔCt The algorithm was used to analyze the difference of MIR503HG between the two groups. The primer sequences used were as follows:
[0044] MIR503HG:
[0045] forward: 5'cccccaacaaaggaacacta3'; as shown in SEQ ID NO.1.
[0046] reverse: 5'acttgggtggttttcaatgc3'; as shown in SEQ ID NO.2.
[0047] β-actin:
[0048] forward: 5'gggacctgactgactacctc3'; as shown in SEQ ID NO.3.
[0049] reverse: 5'tcatactcctgcttgctgat3'; as shown in SEQ ID NO.4.
[0050] The reaction system was as follows: SYBR Premix Ex Taq 10ul; upstream primer 0.8ul; downstream primer 0.8ul; cDNA template 2ul; ROX Reference Dye II 0.4ul; RNase free water 6ul.
[0051] The following reaction was performed in an ABI 7900 real-time fluorescence quantitative PCR instrument:
[0052] Step 1: pre-denaturation at 95°C for 30 seconds;
[0053] Step 2: PCR reaction, a total of 40 cycles, each cycle consisting of denaturation at 95°C for 5 seconds and extension at 60°C for 34 seconds.
[0054] qRT-PCR results showed that the expression of MIR503HG in relatively high-grade pRCC tissues was significantly decreased compared with paired normal renal tissues, and was significantly lower than that in low-grade pRCC tissues. In addition, the expression level of MIR503HG in 21 pRCC tissues with lymph node metastasis events was lower than that in the renal tissues of 46 patients without lymph node metastasis.
[0055] Fluorescence in situ hybridization (FISH):
[0056] 1) Fix and dehydrate renal tumor tissue and normal renal tissue samples;
[0057] 2) Add lncRNA-MIR503HG probe to the hybridization buffer and perform in situ hybridization using an in situ hybridization kit.
[0058] 3) The cell nuclei were stained with DAPI and observed under a fluorescence microscope.
[0059] according to Figure 4 The qRT-PCR results in A were used to obtain the MIR503HG mRNA levels, which were further sorted, and the median of the entire set of data was selected as the cutoff point between the high MIR503HG group and the low MIR503HG group. Kaplan-Meier survival analysis showed that the survival time of patients with low expression of MIR503HG was shorter than that of patients with high expression of MIR503HG. Figure 4 B Fluorescence in situ hybridization technology verified that MIR503HG was lowly expressed in tumor samples with lymph node metastasis, showing a clear negative correlation.
[0060] Example 5 MIR503HG inhibits the lumen formation ability of lymphatic vessels in pRCC cells.
[0061] 1) Tube formation experiment
[0062] Since tumor cells can secrete a variety of growth factors to induce angiogenesis, lumen formation reflects the early process of capillaries and is the most complete indicator for in vitro examination of endothelial cell function. In vitro, endothelial cells are inoculated on a certain substrate and tend to form a reticular structure. The vascular results can be quantitatively analyzed by taking pictures, observing and counting.
[0063] 1) Matrigel preparation: Place Matrigel in an ice box and place in a 4°C refrigerator overnight the day before the experiment to allow the gel to slowly melt overnight. (Note: Also prepare some 4°C pre-cooled pipette tips for sucking up Matrigel);
[0064] 2) Gel: After the matrix gel is frozen and thawed on the next day, prepare for aliquoting. Mix the matrix gel with a pre-cooled pipette tip, pre-cool the EP tube in advance, and aliquot each 500uL. During the operation, the matrix gel must always be kept in an ice box;
[0065] 3) Glue laying: Pre-cool the 96-well plate in advance, add 50 μL / well of matrix gel to the 96-well plate, avoid generating bubbles when adding, and place in a cell culture incubator for 60 minutes to allow it to solidify;
[0066] 4) Collect cells: add 1 mL of trypsin containing EDTA to digest the cells. After complete digestion, add serum-containing culture medium to terminate digestion. After counting, resuspend the cells in culture medium and adjust the cell density to 1-2×104 cells / mL;
[0067] 5) After the gel solidifies, take out the 96-well plate, add 100 μL of cell suspension to each well, mark it and place it in a cell culture incubator for routine culture;
[0068] 6) Observe and photograph the cells under a microscope during routine cell culture for 2 to 24 hours;
[0069] 7) Result analysis: Five fields of view were randomly selected under a 100X microscope to observe and count the number of endothelial cell tubes. Image J software was used to evaluate the length of each tube;
[0070] To determine whether MIR503HG could affect RCC lymph node progression, as expected, the tube formation experiment suggested that the ACHN / CAKI-2-si-MIR503HG culture system significantly promoted the tube formation level of HLEC cells.
[0071] Figure 5 The results confirmed that the expression of MIR503HG in tumor cells was inversely proportional to the tube-forming ability of lymphatic endothelial cells.
Claims
1. Use of LncRNA-MIR503HG in the preparation of a biomarker for predicting the progression of lymph node metastasis in renal papillary cell carcinoma.
2. Use of a reagent for detecting LncRNA-MIR503HG in the preparation of a kit for predicting the progression of lymph node metastasis in renal papillary cell carcinoma, wherein the upstream primer sequence for detecting LncRNA-MIR503HG is shown in SEQ ID NO.1, and the downstream primer sequence for detecting LncRNA-MIR503HG is shown in SEQ ID NO.2; the internal reference used for the detection is β-actin, the upstream primer sequence for detecting β-actin is shown in SEQ ID NO.3, and the downstream primer sequence for detecting β-actin is shown in SEQ ID NO.4.
